10x Genomics (TXG) Q2 2026 Earnings Call Transcript
10x Genomics (TXG) reported Q2 2026 earnings, raising full-year revenue guidance despite expected sequential decline in the third quarter. Booked orders for the new Atera platform have surpassed the 2026 shipment target, though manufacturing capacity limits remain a const…
Intelligence analysis by Llama
10x Genomics raised full-year revenue guidance despite expected sequential decline in the third quarter, driven by strong demand for the Atera platform. The company reported that booked orders for Atera have already surpassed the 2026 shipment target, though manufacturing capacity limits remain a constraint.
Imagine you have a super powerful computer that can look at millions of tiny cells in your body and figure out what's going on. That's basically what 10x Genomics is doing with their new Atera platform. They're helping scientists understand how cells work together to make us sick or healthy, and that's really important for finding new treatments for diseases.
Analysis
Atera Demand Drives Transition Dynamics in Spatial Biology Market
The company reported that booked orders for the new Atera platform have already surpassed the 2026 shipment target, though manufacturing capacity limits remain a constraint for the second half of the year. This is a positive sign for the company's growth prospects, as Atera demand is driving the transition dynamics in the spatial biology market.
AI Applications Drive Significant Demand for High-Throughput Assays
Management stated that artificial intelligence applications are driving significant demand for high-throughput assays like Flex Apex and the integration of the Proteintech Genomics acquisition to enhance multi-omics capabilities. CEO Saxonov estimated the maximum pull-through for the Atera platform to be between $1.5 million to $3 million per instrument, approximately double the capacity of the Xenium system.
AI Becoming a Structural Tailwind for the Company
CEO Saxonov stated, "Today, most significant biological data generation efforts are conceived, at least in part, with the goal of training AI models." This suggests that AI is becoming a structural tailwind for the company, as virtual biology models require the high-resolution, massive-scale data generated by the company's single-cell and spatial technologies.
Key points
- 10x Genomics raised full-year revenue guidance despite expected sequential decline in the third quarter.
- Booked orders for the new Atera platform have already surpassed the 2026 shipment target.
- Manufacturing capacity limits remain a constraint for the second half of the year.
- AI applications are driving significant demand for high-throughput assays like Flex Apex.
- The company is integrating the Proteintech Genomics acquisition to enhance multi-omics capabilities.
If the Atera platform continues to drive strong demand, the company's revenue growth could accelerate in the second half of the year. Additionally, the integration of the Proteintech Genomics acquisition could enhance the company's multi-omics capabilities, leading to new opportunities for growth.
However, the company's manufacturing capacity limits could remain a constraint for the second half of the year, potentially leading to a sequential decline in revenue. Additionally, the company's reliance on AI applications could make it vulnerable to changes in the AI landscape.
